BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HUYABIO International\, LLC. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies HUYABIO International\, LLC.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07318649-2124@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:GH21: Phase 2 readout est. (NCT07318649)
DESCRIPTION:GH21\, phase 2.\nStudy: Phase 2 Clinical Study to Evaluate the 
 Efficacy\, Safety\, Tolerability\, and Pharmacokinetics of GH21 Capsules C
 ombined With D-1553 Tablets in Subjects With Locally Advanced or Metastati
 c Solid Tumors With the KRASG12C Mutation\nEstimated primary completion: 3
 0 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gh21
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 18649
URL:https://assetmemo.bio/drug/gh21#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435455-2124@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:GH21: Phase 1/2 readout est. (NCT06435455)
DESCRIPTION:GH21\, phase 1/2.\nStudy: GH21 Combined With D-1553 in KRAS G12
 C Mutant Advanced Solid Tumors\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/gh21#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06435455
URL:https://assetmemo.bio/drug/gh21#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242274-2566@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JMKX001899: Phase 3 readout est. (NCT07242274)
DESCRIPTION:JMKX001899\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or
  Metastatic KRAS G12C-Mutant NSCLC\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jmkx001899#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0724
 2274
URL:https://assetmemo.bio/drug/jmkx001899#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497985-2286@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Chidamide: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Chidamide\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 idinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Color
 ectal Cancer Patients\nEstimated primary completion: 31 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446725-2124@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:GH21: Phase 1/2 readout est. (NCT07446725)
DESCRIPTION:GH21\, phase 1/2.\nStudy: A Study to Evaluate Safety\, PK and E
 fficacy of GH55 in Combination With GH21 in Patients With Solid Tumors\nEs
 timated primary completion: 30 October 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gh21#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07446725
URL:https://assetmemo.bio/drug/gh21#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947967-2286@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Chidamide: Phase 3 readout est. (NCT06947967)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: Tucid
 inostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymp
 homa With Follicular Helper of T Cell Phenotype\nEstimated primary complet
 ion: December 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06947967
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
